SUMMARY

• RYBREVANT (amivantamab-vmjw) is a low fucose, fully human immunoglobulin G1 (IgG1)-based bispecific antibody with immune cell-directing activity that targets epidermal growth factor receptor (EGFR) mutations and mesenchymal-epithelial transition (MET) mutations and amplifications in non-small cell lung cancer (NSCLC).¹
• Administer the diluted RYBREVANT solution by intravenous (IV) infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.2 micrometer). Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), polyvinyl chloride (PVC), polypropylene (PP), or polyethylene (PE). The administration set with the filter must be primed with either 5% dextrose injection or 0.9% sodium chloride injection prior to the initiation of each RYBREVANT infusion.²
• Please refer to the DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS sections of the full Prescribing Information.²

DOSe administration procedures in the CHRYSALIS study

The information provided in this section summarizes dose administration procedures followed by investigators in the CHRYSALIS study.³ These are not recommendations for individual patient care. Dose administration should be based on the clinical judgment of the treating physician.

• The IV administration sets were primed with 15-25 mL of 5.0% dextrose (glucose) solution or 0.9% normal saline solution prior to infusing RYBREVANT. This was one of the mitigation strategies implemented to reduce the risks associated with infusionrelated reactions (IRRs), including reducing the rate of RYBREVANT initial infusion and allowing for infusion interruption at the first signs of IRR.³

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and DerwentDrug File (and/or other resources, including internal/external databases) was conducted on 25 July 2024.